ImmunoPET: concept, design, and applications
W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
[HTML][HTML] Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
G Crișan, NS Moldovean-Cioroianu… - International Journal of …, 2022 - mdpi.com
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
[HTML][HTML] Insight into the Development of PET Radiopharmaceuticals for Oncology
While the development of positron emission tomography (PET) radiopharmaceuticals
closely follows that of traditional drug development, there are several key considerations in …
closely follows that of traditional drug development, there are several key considerations in …
Novel redirected T–cell Immunotherapies for advanced prostate cancer
TB Dorff, V Narayan, SJ Forman, PD Zang… - Clinical Cancer …, 2022 - AACR
Immunotherapy has failed to achieve durable remissions in advanced prostate cancer
patients. More potent T-cell–redirecting strategies may be needed to overcome the …
patients. More potent T-cell–redirecting strategies may be needed to overcome the …
[HTML][HTML] Treating prostate cancer by antibody–drug conjugates
M Rosellini, M Santoni, V Mollica, A Rizzo… - International journal of …, 2021 - mdpi.com
Prostate cancer is the most frequent malignancy in the worldwide male population; it is also
one of the most common among all the leading cancer-related death causes. In the last two …
one of the most common among all the leading cancer-related death causes. In the last two …
[HTML][HTML] STEAP1–4 (six-transmembrane epithelial antigen of the prostate 1–4) and their clinical implications for prostate cancer
Simple Summary Despite recent therapeutic advances in the treatment of prostate cancer,
metastatic castration-resistant prostate cancer continues to cause significant morbidity and …
metastatic castration-resistant prostate cancer continues to cause significant morbidity and …
[HTML][HTML] Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
Background The prognosis for metastatic Ewing sarcoma family of tumors (EFT) is still poor
despite high-dose chemotherapy and radiation treatment. Immunotherapies hold promise …
despite high-dose chemotherapy and radiation treatment. Immunotherapies hold promise …
Zirconium immune-complexes for PET molecular imaging: current status and prospects
L Melendez-Alafort, G Ferro-Flores, L De Nardo… - Coordination Chemistry …, 2023 - Elsevier
Diagnostic molecular images, obtained by positron emission tomography (PET), have
successfully functioned as sensitive tools for detecting and monitoring the treatment of …
successfully functioned as sensitive tools for detecting and monitoring the treatment of …
[HTML][HTML] 89Zr-PET imaging in humans: a systematic review
MS De Feo, M Pontico, V Frantellizzi, F Corica… - Clinical and …, 2022 - Springer
Purpose The remarkable amount of preclinical data achieved on 89 Zr-PET imaging led to a
significant clinical translation, concerning mainly immuno-PET applications. The aim of this …
significant clinical translation, concerning mainly immuno-PET applications. The aim of this …
Molecular imaging of prostate cancer targeting CD46 using immunoPET
Purpose: We recently identified CD46 as a novel therapeutic target in prostate cancer. In this
study, we developed a CD46-targeted PET radiopharmaceutical,[89Zr] DFO-YS5, and …
study, we developed a CD46-targeted PET radiopharmaceutical,[89Zr] DFO-YS5, and …